QPPV.COM KNOWLEDGE ASSESSMENT

Ravulizumab: Classification, Mechanism, Safety and Pharmacovigilance Assessment

Test your understanding of the concepts covered by Ravulizumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Which information is essential when assessing deterioration after switching from eculizumab to ravulizumab?

Only the date of the patient’s first-ever complement inhibitor treatment The last eculizumab dose, first ravulizumab dose, administered dose, body weight and disease markers around the transition Only whether the patient had previously received antibiotics The patient’s unrelated vaccination history without treatment dates

Question 2 of 10 Why is exact biological product and batch traceability particularly important in a serious ravulizumab reaction?

It replaces the need to assess clinical causality It supports investigation of product-specific or batch-related issues and allows reliable reconstruction of exposure It is relevant only when the patient has no known indication It is unnecessary for biological medicines with a defined active substance

Question 3 of 10 What is the principal pharmacokinetic consequence of ravulizumab’s molecular engineering compared with eculizumab?

More rapid renal elimination of unbound antibody Longer systemic exposure through pH-dependent C5 release and FcRn-mediated recycling Permanent covalent binding to C5 Reduced affinity for FcRn, resulting in faster antibody degradation

Question 4 of 10 Why does ravulizumab treatment create a characteristic susceptibility to invasive meningococcal disease?

C5 blockade impairs the terminal complement function important for defence against Neisseria Ravulizumab suppresses antibody production against all respiratory pathogens The antibody directly increases bacterial adhesion to erythrocytes FcRn recycling selectively reduces neutrophil activity against meningococci

Question 5 of 10 Which statement best explains why vaccination does not eliminate meningococcal risk during ravulizumab treatment?

Vaccines are ineffective in all patients receiving monoclonal antibodies Vaccination can reduce risk but does not restore terminal complement while C5 remains blocked Ravulizumab prevents vaccine antigens from being presented to T cells Meningococcal disease in treated patients is always caused by non-vaccine serogroups

Question 6 of 10 Why should loss-of-efficacy analyses for ravulizumab be stratified by indication?

The antibody binds a different C5 epitope in each disease Each disease has different manifestations and objective markers of inadequate disease control Only PNH patients can experience treatment failure Stratification is needed solely to compare vaccine uptake

Question 7 of 10 A patient receiving ravulizumab develops suspected meningococcal sepsis despite documented vaccination. What is the most appropriate pharmacovigilance interpretation?

Vaccination proves that ravulizumab cannot have contributed to susceptibility The case should be excluded because the event is an expected infection The event remains medically important and should be assessed in the context of persistent C5 blockade Only a confirmed culture-positive case should be followed up

Question 8 of 10 Which aggregate-analysis practice would most likely obscure a clinically meaningful signal?

Reviewing meningococcal disease as a dedicated medically important case series Stratifying loss-of-efficacy events by indication Pooling PNH haemolysis, aHUS TMA, gMG worsening and NMOSD relapse into one undifferentiated failure category Reviewing transition cases separately from routine maintenance treatment

Question 9 of 10 A patient treated for aHUS develops thrombocytopenia and renal deterioration. Which approach best reflects the article’s pharmacovigilance framework?

Assume recurrent complement-mediated TMA because the patient receives a C5 inhibitor Assess for recurrent TMA while also considering infection, malignant hypertension, transplant injury and other causes Interpret the findings only through neurological disease measures Conclude that ravulizumab is ineffective whenever creatinine rises

Question 10 of 10 Which statement best distinguishes a disease-specific lack-of-efficacy event from simple pharmacological failure?

Any clinical worsening automatically proves that C5 inhibition failed Clinical worsening should be interpreted with exposure continuity, disease-specific markers and competing explanations Only laboratory abnormalities can constitute lack of efficacy A lack-of-efficacy event cannot occur after treatment interruption

Ravulizumab: Classification, Mechanism, Safety and Pharmacovigilance Assessment

Cookie Settings